Pharmacogenomics · 2026
UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Najaflu Malihe, Neufeld Ellis J, Mansourian Marjan, Ghanavat Majid, Salehi Mansoor
Аннотация
AIMS: Deferiprone, an iron chelator, causes variable adverse drug reactions (ADRs) in β-thalassemia patients, suggesting a role for pharmacogenetic factors. To address the lack of comprehensive pharmacogenetic data, this study investigated the association between four common UGT1A6 variants - the primary enzyme metabolizing deferiprone - and the occurrence of specific ADRs, considering relevant clinical and personal characteristics.
PATIENTS & METHODS: A retrospective cohort of 178 Iranian β-thalassemia major patients on deferiprone was studied. ADRs - arthralgia, gastrointestinal (GI) complications, neutropenia, and liver enzyme elevations - were defined using clinical guidelines, confirmed by medical records, and supplemented by questionnaires. Four UGT1A6 polymorphisms were genotyped, and associations were evaluated using a complication-specific framework and diplotype - haplotype analyses, adjusting for ten demographic, clinical, and treatment variables.
RESULTS: Overall ADR incidence was not significantly associated with individual SNPs. Stratified analysis revealed that the AA - GC diplotype (rs2070959-rs1105879) was associated with reduced arthralgia risk (OR = 0.28, p = 0.022), whereas the GC - AC diplotype was linked to increased GI complication risk (OR = 5.48, p = 0.007) and showed a near-significant association with neutropenia. Female sex was associated only with increased GI complications (p = 0.002).
CONCLUSIONS: Specific UGT1A6 diplotypes and sex are differentially associated with distinct deferiprone-related ADRs. A complication-specific pharmacogenetic approach can improve understanding of deferiprone-related ADRs.
PATIENTS & METHODS: A retrospective cohort of 178 Iranian β-thalassemia major patients on deferiprone was studied. ADRs - arthralgia, gastrointestinal (GI) complications, neutropenia, and liver enzyme elevations - were defined using clinical guidelines, confirmed by medical records, and supplemented by questionnaires. Four UGT1A6 polymorphisms were genotyped, and associations were evaluated using a complication-specific framework and diplotype - haplotype analyses, adjusting for ten demographic, clinical, and treatment variables.
RESULTS: Overall ADR incidence was not significantly associated with individual SNPs. Stratified analysis revealed that the AA - GC diplotype (rs2070959-rs1105879) was associated with reduced arthralgia risk (OR = 0.28, p = 0.022), whereas the GC - AC diplotype was linked to increased GI complication risk (OR = 5.48, p = 0.007) and showed a near-significant association with neutropenia. Female sex was associated only with increased GI complications (p = 0.002).
CONCLUSIONS: Specific UGT1A6 diplotypes and sex are differentially associated with distinct deferiprone-related ADRs. A complication-specific pharmacogenetic approach can improve understanding of deferiprone-related ADRs.